Fundz

RenovoRx reported raising $6.11 Million in an initial SEC Form D filing, from an offering of $15 Million

PUBLIC · RNXTFeb 09, 2024$6.1M of $15M raised

Amount Raised

$6.11 Million

$6.11 Million per company press release (Apr 8, 2024)

Round Type

Venture

Los AltosBiotechnologyHealthcare

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as RenovoRx that raised within 45 days of this round, from Fundz verified event records.

  • Alumis raised $259M (Series C) on March 7, 2024.
  • Alumis raised $259M (Series C) on March 7, 2024.
  • Azora Therapeutics, Inc. (DE) raised $288K (Seed) on March 6, 2024.
  • Alumis raised $259M (Series C) on March 6, 2024.
  • Alumis raised $259M (Series C) on March 6, 2024.
  • Argonaut Manufacturing Services raised $45M (Funding Round) on March 5, 2024.

Who to call at RenovoRx, and when

A new round usually means RenovoRx is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day RenovoRx raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at RenovoRx, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at RenovoRx. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

RenovoRx

Location

Los Altos, California, United States

About

RenovoRx, Inc. (Nasdaq: RNXT) is developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. FDA-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic IV therapy. RenovoRx’s novel approach to targeted drug-delivery offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment RenovoRx raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsRyan W., SVP, Head of Corporate Strategy & Partn…See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for RenovoRx's next move

See what Strategic adds

RenovoRx raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.